Sebastiano Buti1, Melissa Bersanelli2, Francesca Maines3, Gaetano Facchini4, Francesco Gelsomino5, Fable Zustovich6, Matteo Santoni7, Elena Verri8, Ugo De Giorgi9, Cristina Masini10, Franco Morelli11, Maria Giuseppa Vitale12, Teodoro Sava13, Giuseppe Prati14, Carmelinda Librici15, Anna Paola Fraccon16, Giuseppe Fornarini17, Marco Maruzzo18, Francesco Leonardi1, Orazio Caffo3. 1. University Hospital of Parma, Medical Oncology, Parma, Italy. 2. University Hospital of Parma, Medical Oncology, Parma, Italy. Electronic address: bersamel@libero.it. 3. Santa Chiara Hospital, Medical Oncology, Trento, Italy. 4. Fondazione Pascale National Cancer Institute, Napoli, Italy. 5. Sant'Orsola-Malpighi Hospital, Medical Oncology, Bologna, Italy. 6. San Martino Hospital, Medical Oncology, Belluno, Italy. 7. University Hospital of Ancona, Medical Oncology, Ancona, Italy. 8. European Institute of Oncology, Milano, Italy. 9. Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy. 10. Arcispedale S. Maria Nuova, Medical Oncology, Reggio Emilia, Italy. 11. Casa Sollievo della Sofferenza Hospital, Medical Oncology, San Giovanni Rotondo, Italy. 12. Antonio Cardarelli Hospital, Medical Oncology, Napoli, Italy. 13. Azienda Ospedaliera Universitaria Integrata of Verona, Medical Oncology, Verona, Italy. 14. Hospital of Guastalla, Medical Oncology, Guastalla, Italy. 15. Ospedali Riuniti Villa Sofia-Cervello Hospital, Medical Oncology, Palermo, Italy. 16. Pederzoli Hospital, Medical Oncology, Peschiera, Italy. 17. IRCCS Azienda Ospedaliera Universitaria San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Medical Oncology n°1, Genova, Italy. 18. Istituto Oncologico Veneto, IOV-IRCCS, Medical Oncology 1 Unit, Padova, Italy.
Abstract
INTRODUCTION: Pazopanib is a standard first-line treatment for metastatic clear-cell renal cell carcinoma (ccRCC). Very few data on its activity in non-clear-cell renal cell carcinoma (nccRCC) are currently available. The aim of this study was to retrospectively analyze efficacy and toxicity of pazopanib in nccRCC patients. PATIENTS AND METHODS: Records from advanced nccRCC patients (consecutive sample) treated with first-line pazopanib between 2010 and 2015 at 17 Italian centers were reviewed. Response rate, progression-free survival (PFS), and overall survival (OS) were evaluated. Univariate and descriptive analyses were performed. RESULTS: Thirty-seven patients with nccRCC were treated with first-line pazopanib; 51% had papillary histology, 24% chromophobe, 22% unclassified, and 3% had Xp11.2 translocation. Dose reductions/temporary interruptions for toxicity were required in 46% of cases. Grade (G) 3/4 toxicity was seen in 32%, G1/2 in 89% of cases; 81% achieved disease control, with 10 partial responses (27%) and 20 cases of stable disease (54%); 16% of patients had disease progression as best response. Median PFS and OS were 15.9 and 17.3 months, respectively. In univariate analysis, nephrectomy (P = .020), Memorial Sloan Kettering Cancer Center (MSKCC) score (P < .001), basal neutrophil/lymphocyte ratio (NLR; P = .009) and performance status (PS) (P = .001) were associated with PFS; MSKCC score (P < .001), International Metastatic Renal Cell Carcinoma Database Consortium score (P = .003), PS (P < .0001), nephrectomy (P = .002), histology (P = .035), dose reductions/interruptions (P = .039), best response to treatment (P < .001), and NLR (P = .008) were associated with OS. CONCLUSION: In nccRCC patients, treatment with pazopanib was effective and feasible; dose reductions required for toxicity were similar as expected in ccRCC.
INTRODUCTION:Pazopanib is a standard first-line treatment for metastatic clear-cell renal cell carcinoma (ccRCC). Very few data on its activity in non-clear-cell renal cell carcinoma (nccRCC) are currently available. The aim of this study was to retrospectively analyze efficacy and toxicity of pazopanib in nccRCC patients. PATIENTS AND METHODS: Records from advanced nccRCC patients (consecutive sample) treated with first-line pazopanib between 2010 and 2015 at 17 Italian centers were reviewed. Response rate, progression-free survival (PFS), and overall survival (OS) were evaluated. Univariate and descriptive analyses were performed. RESULTS: Thirty-seven patients with nccRCC were treated with first-line pazopanib; 51% had papillary histology, 24% chromophobe, 22% unclassified, and 3% had Xp11.2 translocation. Dose reductions/temporary interruptions for toxicity were required in 46% of cases. Grade (G) 3/4 toxicity was seen in 32%, G1/2 in 89% of cases; 81% achieved disease control, with 10 partial responses (27%) and 20 cases of stable disease (54%); 16% of patients had disease progression as best response. Median PFS and OS were 15.9 and 17.3 months, respectively. In univariate analysis, nephrectomy (P = .020), Memorial Sloan Kettering Cancer Center (MSKCC) score (P < .001), basal neutrophil/lymphocyte ratio (NLR; P = .009) and performance status (PS) (P = .001) were associated with PFS; MSKCC score (P < .001), International Metastatic Renal Cell Carcinoma Database Consortium score (P = .003), PS (P < .0001), nephrectomy (P = .002), histology (P = .035), dose reductions/interruptions (P = .039), best response to treatment (P < .001), and NLR (P = .008) were associated with OS. CONCLUSION: In nccRCC patients, treatment with pazopanib was effective and feasible; dose reductions required for toxicity were similar as expected in ccRCC.
Authors: Sebastien J Hotte; Anil Kapoor; Naveen S Basappa; Georg Bjarnason; Christina Canil; Henry J Conter; Piotr Czaykowski; Jeffrey Graham; Samantha Gray; Daniel Y C Heng; Pierre I Karakiewicz; Christian Kollmannsberger; Aly-Khan A Lalani; Scott A North; François Patenaude; Denis Soulières; Phillippe Violette; Eric Winquist; Lori A Wood; Shaan Dudani; Ranjena Maloni; M Neil Reaume Journal: Can Urol Assoc J Date: 2019-10 Impact factor: 1.862
Authors: M Lázaro; B P Valderrama; C Suárez; G de-Velasco; C Beato; I Chirivella; A González-Del-Alba; N Laínez; M J Méndez-Vidal; J A Arranz Journal: Clin Transl Oncol Date: 2020-01-28 Impact factor: 3.405
Authors: Nieves Martínez Chanzá; Wanling Xie; Mehmet Asim Bilen; Hannah Dzimitrowicz; Jarred Burkart; Daniel M Geynisman; Archana Balakrishnan; I Alex Bowman; Rohit Jain; Walter Stadler; Yousef Zakharia; Vivek Narayan; Benoit Beuselinck; Rana R McKay; Abhishek Tripathi; Russell Pachynski; Andrew W Hahn; JoAnn Hsu; Sumit A Shah; Elaine T Lam; Tracy L Rose; Anthony E Mega; Nicholas Vogelzang; Michael R Harrison; Amir Mortazavi; Elizabeth R Plimack; Ulka Vaishampayan; Hans Hammers; Saby George; Naomi Haas; Neeraj Agarwal; Sumanta K Pal; Sandy Srinivas; Benedito A Carneiro; Daniel Y C Heng; Dominick Bosse; Toni K Choueiri; Lauren C Harshman Journal: Lancet Oncol Date: 2019-02-28 Impact factor: 41.316
Authors: Guilherme Nader Marta; Pedro Isaacsson Velho; Renata R C Bonadio; Mirella Nardo; Sheila F Faraj; Manoel Carlos L de Azevedo Souza; David Q B Muniz; Diogo Assed Bastos; Carlos Dzik Journal: Pathol Oncol Res Date: 2020-06-24 Impact factor: 3.201
Authors: Sumanta K Pal; Bradley McGregor; Cristina Suárez; Che-Kai Tsao; William Kelly; Ulka Vaishampayan; Lance Pagliaro; Benjamin L Maughan; Yohann Loriot; Daniel Castellano; Sandy Srinivas; Rana R McKay; Robert Dreicer; Thomas Hutson; Sarita Dubey; Scott Werneke; Ashok Panneerselvam; Dominic Curran; Christian Scheffold; Toni K Choueiri; Neeraj Agarwal Journal: J Clin Oncol Date: 2021-09-07 Impact factor: 44.544
Authors: M Neil Reaume; Naveen S Basappa; Lori Wood; Anil Kapoor; Georg A Bjarnason; Normand Blais; Rodney H Breau; Christina Canil; Patrick Cheung; Henry J Conter; Sebastien J Hotte; Claudio Jeldres; Michael A S Jewett; Pierre I Karakiewicz; Christian Kollmannsberger; Francois Patenaude; Alan So; Denis Soulières; Peter Venner; Phillippe Violette; Pawel Zalewski; Heather Chappell; Scott A North Journal: Can Urol Assoc J Date: 2017-10 Impact factor: 1.862
Authors: Darren R Feldman; Yasser Ged; Chung-Han Lee; Andrea Knezevic; Ana M Molina; Ying-Bei Chen; Joshua Chaim; Devyn T Coskey; Samuel Murray; Satish K Tickoo; Victor E Reuter; Sujata Patil; Han Xiao; Jahan Aghalar; Arlyn J Apollo; Maria I Carlo; Robert J Motzer; Martin H Voss Journal: Cancer Date: 2020-09-25 Impact factor: 6.860